Introduction {#Sec1}
============

Pulmonary hypertension (PH) is a progressive and life threatening condition characterized by a progressive increase in pulmonary vascular resistance resulting in right heart failure and death. PH is classified in five subgroups according to etiology, of which one is pulmonary arterial hypertension (PAH) \[[@CR1]\]. Prognosis in idiopathic PH, a subgroup of PAH, remains poor \[[@CR2]\]. PAH is defined by a mean pulmonary artery pressure (PAP) \>25 mmHg at rest or \>30 mmHg during exercise \[[@CR3]\]. Doppler echocardiography allows indirect measurement of PAP from valvular regurgitation and detects corresponding changes in right heart morphology and function \[[@CR4]--[@CR6]\]. In clinical practice, right heart catheterization is mandatory to confirm the presence of PAH and to test vasoreactivity of the pulmonary circulation \[[@CR7]\].

Echocardiographically derived peak and mean PAP have been reported to correlate (*r* = 0.73--0.94) with invasive measurements in humans \[[@CR8]--[@CR10]\]. However, these measurements require the presence of right-sided valvular regurgitation. Tricuspid valve regurgitation (TR) can be detected in only 39--86% of patients and in only 44--96% of these cases does the regurgitation produce enough signal for pressure measurement to be made possible \[[@CR4]\]. Detecting a good signal from pulmonary valve regurgitation also requires technical competence but has approximately the same yield as TR signals \[[@CR11]\]. Furthermore, PAP measurement without flow information can be misleading especially in cases with elevated PAP due to high cardiac output but normal pulmonary vascular resistance (PVR). Therefore, additional non-invasive parameters for evaluation of PAH are much needed.

Echocardiographically derived PVR has proven to be a valuable parameter \[[@CR12], [@CR13]\]. However, this measurement also requires the presence of TR. Tissue Doppler derived isovolumetric relaxation time (IVRT') of the right ventricle (RV) predicts elevated PAP in humans \[[@CR14]\]. Pulmonary artery acceleration time (PAAT) correlated (*r* = 0.84--0.89) with invasive PAP especially in mild to moderate PAH and was prognostic as well \[[@CR15]\]. However, except for PAAT, all other measurements require acceptable Doppler image quality. Three different velocity profiles (normal round-shaped, intermediate and triangular) were characterized corresponding to the severity of PAH \[[@CR16], [@CR17]\] (Fig. [1](#Fig1){ref-type="fig"}). Under normal conditions, pulmonary artery flow velocity increases and decreases slowly and symmetrically. In PAH, flow velocity increases and decreases rapidly \[[@CR18], [@CR19]\] due to increased right ventricular stroke work and stiffness in the pulmonary artery leading to altered velocity profiles. The greatest difference in these flow profiles exists during the early deceleration period. However, it has not been shown whether quantification of the pulmonary artery flow deceleration (PAD) is useful for detecting PAH or measuring its severity. Furthermore, observer related variability of the invasive and noninvasive parameters of PAH in rats is relatively unknown.Fig. 1Progression of PAH demonstrated by echocardiography at baseline, and 21 and 35 days after MCT induction. *Columns* represent temporal phases (baseline, day 21, and day 35) and rows five different imaging windows: (1) high parasternal short-axis view is used to detect pulmonary artery flow by pulsed-wave Doppler, right ventricular remodeling by (2) apical four-chamber view, (3) parasternal long-axis, (4) parasternal short-axis views using B-mode (all end-diastolic), and right ventricular thickness by (5) parasternal long-axis through aortic valve using M-mode. Upper row demonstrates different types of pulmonary artery flow profiles regarding to the severity of pulmonary hypertension. Normal, round-shaped flow profile (baseline), intermediate type flow profile with a sharp peak at early systole, decreased acceleration time and increased deceleration (day 21) and triangular flow profile with mid-systolic notching (day 35). Apical four-chamber and both parasternal views show progressive right ventricular dilatation with concomitant decrease of left ventricle. Parasternal long-axis images through aorta using M-mode show progressing right ventricular hypertrophy

We investigated the diagnostic yield of echocardiographically derived TPVR and echocardiographic parameters of PAP in screening PAH in a rat model. Furthermore, we studied whether these non-invasive measurements can be used to measure the severity of PAH by comparing them to invasive measurements. We hypothesized that the echocardiographic parameters TPVR, IVRT', PAAT, PAD, right ventricular area and thickness reliably predict the severity of PAH and are reproducible.

Methods {#Sec2}
=======

Six-week old female RNU-1 (Charles river) nude rats (*n* = 28) were used according to our protocol approved by Institutional animal care and use committee (IACUC). Pulmonary hypertension was induced using intraperitoneal injection of monocrotaline (MCT) (Sigma--Aldrich, St. Louis, MO) with a dose of 75 mg/kg. MCT was dissolved in HCl (hydrochloric acid), diluted with distilled water and administered after adjusting the pH to 7.4. MCT is a pyrrolized alkaloid derived from *Crotalia spectabilis* and its administration into the intraperitoneal cavity is associated with increased pulmonary arterial pressure, increased medial wall thickening, and RV hypertrophy \[[@CR20], [@CR21]\]. The MCT-induced PAH model is widely used and has shown similarities to human idiopathic PAH \[[@CR22], [@CR23]\]. Right heart catheterization and echocardiography were performed within the same day under general anesthesia (2% isofluorane/oxygen 1 l/min). The animals were placed on a heating pad to maintain body temperature at 37--38°C throughout the studies. Studies were performed at baseline, 21 and 35 days after MCT injection.

Invasive measurements by right heart catheterization {#Sec3}
----------------------------------------------------

Lidocaine (6 mg/kg) was administered subcutaneously into the neck of the animal and the right or left external jugular vein was isolated. A 2F microtip catheter (Millar Instruments) was connected via a pressure control unit (Millar Instruments, Houston, TX) to a physiological recorder (Powerlab ML786) and viewed using Chart5 computer software (ADInstruments, Colorado Springs, CO). The catheter was guided into the RV to obtain pressure measurements after calibration. Pulmonary valve pathology was excluded at baseline using echocardiography and therefore right ventricular systolic pressure (RVSP) is similar to the systolic PAP. An average of 15--20 pressure cycles was utilized to obtain final pressure value. Systolic PAP values were employed to determine mean PAP using the following experimental formula: Mean PAP (in mmHg) = 0.61\*systolic PAP + 2 \[[@CR24]\]. Invasive TPVR in dyn·s·cm^−5^ was calculated using the following formula: 80 \* mean PAP (in mmHg)/cardiac output (in liters).

Echocardiography {#Sec4}
----------------

Transthoracic echocardiography was performed by Sequoia C 256 ultrasound device (Acuson Inc., Mountain View, California) with a 15.0 MHz linear or a 3.5 MHz cardiac transducer. Presence of TR was assessed from color Doppler images using a 15.0 MHz transducer. Tricuspid valve was graded as normal if TR was not observed, mild, moderate and severe when regurgitation jet was visually \<20%, 20--50% or \>50% of the right atrial area, respectively. If TR was observed, the regurgitation velocity was assessed by using a 3.5 MHz transducer with continuous wave Doppler. Pulmonary artery flow was measured using pulsed wave Doppler with a sample gate of 1.0 mm at pulmonary valve level but signal for PAAT and PAD measurements were achieved from the right ventricular outflow tract and opening and closing clicks of the pulmonary valve were avoided. By combining pulmonary artery velocity--time integral, pulmonary artery area and heart rate, echocardiographically derived cardiac output was determined as published earlier \[[@CR25]\]. Tissue Doppler was measured from basal lateral wall of the right ventricle in a four-chamber view with a gate of 1--2 mm. Echo-TPVR was measured using four different ways: Echo-TPVR formula-1 (peak TR velocity/right ventricular outflow tract velocity time integral (RVOT VTI)) \[[@CR13]\], Echo-TPVR formula-2 (TPVR (in dyn·s·cm^−5^) = 80 \* mean PAP (in mmHg)/cardiac output (in liters), in which mean PAP is determined from systolic PAP as outlined previously, Echo-TPVR formula-3 (PAAT/RVOT VTI), and Echo-TPVR formula-4 (PAD/RVOT VTI). IVRT' was defined as the interval from the end of S~m~ wave to the beginning of E~a~ wave \[[@CR26]\]. PAAT was defined as the interval from the onset to the maximal velocity of forward pulmonary artery flow and PAD as the first linear deceleration period after maximal velocity. Right ventricular thickness was measured at diastole from parasternal long axis view using M-mode. Apical four-chamber view was employed to measure end-diastolic right ventricular area.

Statistical analysis {#Sec5}
--------------------

Statistical analysis was performed using either SPSS 16 (SSPP Inc, Chicago, IL, USA) or SAS (SAS Institute, Cary, NC, USA). Statistical difference between the parameters at baseline, 21 and 35 days after PAH induction was assessed with repeated-measures analysis of variance with Tukey's correction, except for those without successful measurements at baseline, which were assessed by paired *t*-test. Pearson or Spearman correlation coefficients were appropriately calculated. Bland--Altman method was used for comparing parameters when appropriate \[[@CR27]\]. To obtain intraobserver and interobserver variability of the invasive and noninvasive parameters, ten studies were analyzed by two blinded reviewers. Observer variability is expressed using coefficient of variation (CV), mean difference and intraclass correlation \[[@CR28]\]. CV for repeated measurements was calculated by dividing SD with a mean and expressed as percentage values. Mean difference (%) was calculated using the following formula (\|measurement 1 − measurement 2\|)/((measurement 1 + measurement 2)/2) \* 100. ROC curves were generated to explore an optimal cut-off value of the studied parameters to discriminate animals with PAH from non-PAH animals. An area under each ROC curve (AUC) was calculated. Positive and negative predictive values, sensitivity, specificity and accuracy were calculated using standard formulas. *P*-value less than 0.05 was considered significant. The results are expressed as mean ± SD.

Results {#Sec6}
=======

A total of 75 echocardiographies were performed and analyzed in rats with variable degrees of PAP at the combined time-points of baseline, 21 and 35 days after MCT injection. Twenty-eight animals had echos performed at baseline and at 21 days. However, only 19 animals had the echocardiography at day 35 due to the mortality associated with significant PAH. Pulmonary artery flow (Fig. [1](#Fig1){ref-type="fig"}) was measured successfully by echocardiography in all animals whereas invasive PAP measurement was technically feasible in only 62 out of 75 (83%) studies, mostly due to the technically challenging nature of accessing murine right ventricle in PAH. There was no detectable TR in any of the study animals at baseline. At day 35, up to 84% of the animals had TR. Ten mild, ten moderate and 14 severe TR were noted in total. Detailed hemodynamic data is presented in Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of rats at baseline and 21 and 35 days after MCT injection for induction of pulmonary arterial hypertensionBaseline (*n* = 28)Day 21 (*n* = 28)Day 35 (*n* = 19)Baseline vs. day 21Day 21 vs. day 35Baseline vs. day 35Weight (g)150.0 ± 26.9170.9 ± 18.0184.6 ± 24.7*P* = 0.04*P* = 0.13*P* \< 0.001Heart rate (bpm)373 ± 32344 ± 41304 ± 43*P* = 0.02*P* = 0.002*P* \< 0.001Invasive systolic PAP (mmHg)29.6 ± 3.739.5 ± 15.565.3 ± 14.9*P* = 0.01*P* \< 0.001*P* \< 0.001Invasive mean PAP (mmHg)20.1 ± 2.326.1 ± 9.541.8 ± 9.1*P* = 0.01*P* \< 0.001*P* \< 0.001Invasive TPVR (10^4^\*dyn·s·cm^−5^)2.3 ± 0.83.5 ± 2.36.4 ± 3.9*P* = 0.24*P* \< 0.01*P* \< 0.001Tricuspid regurgitation (%)0%64%84%*P* \< 0.001*P* = 0.15*P* \< 0.001Echo systolic PAP (mmHg)NA66.4 ± 18.883.6 ± 16.2NA*P* = 0.03NAEcho TPVR (ms^−1^m)NA142 ± 61149 ± 60NA*P* = 0.57NAEcho TPVR (10^4^\*dyn·s·cm^−5^)NA7.7 ± 2.89.2 ± 5.9NA*P* = 0.52NAIVRT' (ms)20.2 ± 9.420.1 ± 16.929.0 ± 18.3*P* = 1.00*P* = 0.29*P* = 0.29Pulmonary artery acceleration time (ms)36.3 ± 5.527.7 ± 6.321.7 ± 4.5*P* \< 0.001*P* \< 0.01*P* \< 0.001Pulmonary artery deceleration (m/s^2^)7.3 ± 2.411.7 ± 6.616.6 ± 4.7*P* \< 0.01*P* \< 0.01*P* \< 0.001Right ventricular cardiac output (ml)77.7 ± 20.665.5 ± 21.863.0 ± 22.8*P* = 0.12*P* = 0.93*P* = 0.08Right ventricular area (cm^2^)0.18 ± 0.040.26 ± 0.090.31 ± 0.10*P* = 0.02*P* \< 0.001*P* \< 0.001Right ventricular thickness (mm)0.42 ± 0.070.55 ± 0.170.77 ± 0.18*P* = 0.02*P* = 0.10*P* \< 0.001All data is presented as mean ± SDSee Methods for calculations*PAP* pulmonary artery pressure; *TPVR* total pulmonary vascular resistance; *NA* not available; *IVRT'* tissue Doppler derived isovolumetric relaxation time of the right ventricle

The correlation between echocardiographically derived TPVR with invasive TPVR measurements were as follows: *r* = 0.85, *P* \< 0.001, *r* = 0.92, *P* \< 0.001, *r* = 0.08, *P* = 0.56 and *r* = 0.70, *P* \< 0.001 for Echo-TPVR formula 1, 2, 3 and 4, respectively (Fig. [2](#Fig2){ref-type="fig"}a, b). Echo-derived TPVR using formula 1 and 2 was measurable in only 23% (14 out of 62) of the studies with successful invasive measurements; the rest of the animals had an insufficient degree of TR for evaluation. Figure [2](#Fig2){ref-type="fig"}c demonstrates Bland--Altman plot between Echo-TPVR formula-2 and invasive TPVR measurement. Additionally, one of the TPVR measurement pair is noted to be radically different than the others but the observed correlations between echo-TPVR-1 and 2 versus invasive-TPVR are *r* = 0.67, *P* = 0.005 and *r* = 0.70, *P* \< 0.001, respectively, even after excluding this pair. The measurement of IVRT' had a weak correlation (*r* = 0.38, *P* = 0.02) with invasive PAP and it was measurable in 56% of the studies. PAAT (*r* = −0.74, *P* \< 0.001) and PAD (*r* = 0.75, *P* \< 0.001) had relatively good correlations with invasive PAP (Fig. [3](#Fig3){ref-type="fig"}a, b). Even though echocardiographically derived systolic PAP had a minimal mean difference of 5.4 ± 12.8 mmHg compared to invasive PAP, significant correlation (*r* = 0.38, *P* = 0.18) was not observed between the methods due to small range of observed PAPs using this echo method. Both anatomical measures, right ventricular thickness and right ventricular area, correlated with invasive PAP (*r* = 0.59 and *r* = 0.64, *P* \< 0.001 for both).Fig. 2Correlations between TPVR by right heart catheterization and two different echocardiographic techniques. Echo-TPVR (formula-1) was calculated by dividing tricuspid regurgitation velocity from pulmonary artery velocity time integral (**a**), Echo-TPVR (formula-2) was calculated by the following formula (Echo TPVR = 80 \* mean PAP in mmHg/cardiac output in liters) (**b**). Invasive TPVR was calculated using the previous formula and the mean PAP was derived from systolic PAP using previously validated formula \[[@CR24]\], and Bland--Altman plot between Echo-TPVR formula-2 and invasive TPVR measurement (**c**)Fig. 3Correlation between invasive (right heart catheterization) measurement of PAP and its estimation from echocardiographically derived pulmonary artery acceleration time (**a**) and pulmonary artery deceleration (**b**)

Intraobserver and interobserver variabilities of the studied parameters are presented in Table [2](#Tab2){ref-type="table"}. Intraobserver and interobserver variability of the invasive PAP expressed as coefficient of variation was 1.4 ± 2.0 and 1.3 ± 1.4%. The intraobserver and interobserver variability values for all the non-invasive parameters ranged between 2.6 ± 3.5 and 20.6 ± 27.2%, respectively (Table [2](#Tab2){ref-type="table"}). Observer related variability of invasive TPVR was 7.2 ± 9.3 and 9.1 ± 8.6%. Echo-TPVR formula-1 had lower observer related variability compared to echo-TPVR formula-2.Table 2Intraobserver and interobserver variability of the invasive and noninvasive parameters of pulmonary arterial hypertensionCV%Mean difference (range) %Intraclass correlation (*P*-value)Intraobserver variability Invasive mean PAP (mmHg)1.4 ± 2.01.3 (−6.4--2.4)0.99 (*P* \< 0.001) Invasive TPVR (10^4^\*dyn·s·cm^−5^)7.2 ± 9.312.3 (−10.7--25.4)0.90 (*P* \< 0.001) Echo systolic PAP (mmHg)4.9 ± 3.34.6 (−10.8--7.9)0.97 (*P* \< 0.001) Echo TPVR (ms^−1^m)5.8 ± 4.65.4 (−8.0--14.7)0.95 (*P* \< 0.001) Echo TPVR (10^4^\* dyn·s·cm^−5^)10.1 ± 12.29.5 (−24.2--31.0)0.85 (*P* \< 0.001) IVRT' (ms)7.6 ± 7.08.1 (−13.1--15.2)0.96 (*P* \< 0.001) PAAT (ms)4.8 ± 3.04.6 (−7.5--6.6)0.90 (*P* \< 0.001) PAD (m/s^2^)10.2 ± 6.79.9 (−23.5--9.5)0.94 (*P* \< 0.001) Right ventricular area (cm^2^)11.3 ± 9.48.8 (−18.3--16.4)0.90 (*P* \< 0.001) Right ventricular thickness (mm)8.1 ± 7.25.2 (−16.1--13.2)0.95 (*P* \< 0.001)Interobserver variability Invasive mean PAP (mmHg)1.3 ± 1.41.3 (−1.8--3.7)1.00 (*P* \< 0.001) Invasive TPVR (10^4^\*dyn·s·cm^−5^)9.1 ± 8.68.4 (−16.6--24.6)0.94 (*P* \< 0.001) Echo systolic PAP (mmHg)3.6 ± 3.63.3 (−4.1--9.7)0.98 (*P* \< 0.001) Echo TPVR (ms^−1^m)4.9 ± 1.34.6 (−5.4--7.3)0.98 (*P* \< 0.001) Echo TPVR (10^4^\* dyn·s·cm^−5^)9.7 ± 8.59.0 (−18.4--20.7)0.95 (*P* \< 0.001) IVRT' (ms)20.6 ± 27.222.2 (−84.6--16.0)0.89 (*P* \< 0.001) PAAT (ms)2.6 ± 3.52.4 (−4.1--9.1)0.93 (*P* \< 0.001) PAD (m/s^2^)5.8 ± 5.45.3 (−7.0--14.0)0.98 (*P* \< 0.001) Right ventricular area (cm^2^)11.2 ± 9.39.0 (−14.3--16.2)0.91 (*P* \< 0.001) Right ventricular thickness (mm)8.9 ± 8.65.9 (−15.6--18.3)0.95 (*P* \< 0.001)Values for coefficient of variation (CV) are means ± SD and for mean difference are means and rangeSee Methods for calculations*PAP* pulmonary artery pressure; *TPVR* total pulmonary vascular resistance; *IVRT'* tissue Doppler derived isovolumetric relaxation time of the right ventricle; *PAAT* pulmonary artery acceleration time; *PAD* pulmonary artery deceleration

Diagnostic performance of echocardiographic parameters to detect pulmonary hypertension (mPAP \>25 mmHg) is presented in Table [3](#Tab3){ref-type="table"}. Optimal cut-off values and areas under curve were 28 ms (AUC 0.943) for PAAT, 11.8 m/s^2^ (AUC 0.931) for PAD, 0.56 mm (AUC 0.887) for RV thickness and 0.225 cm^2^ (AUC 0.907) for RV area, respectively. PAAT \<28 ms had the best diagnostic value when accounting all non-invasive parameters. We created two new algorithms of pulmonary flow by combining PAAT \<28 ms and PAD \>11.8 m/s^2^ values (Table [3](#Tab3){ref-type="table"}). The algorithm of PAAT \<28 ms and PAD \>11.8 m/s^2^ has the best specificity of 97.3% and PAAT \<28 ms has the best sensitivity of 86.4%.Table 3Diagnostic performance of echocardiographic parameters to detect pulmonary hypertension (mPAP \>25 mmHg)PAAT \<28 ms (%)PAD \>11.8 m/s^2^ (%)PAAT \<28 ms and PAD \>11.8 m/s^2^ (%)PAAT \<28 ms or PAD \>11.8 m/s^2^ (%)RV thickness \>0.56 mm (%)RV area \>0.225 cm^2^ (%)Sensitivity86.472.768.286.472.782.6Specificity87.887.897.678.094.384.6Negative predictive value79.276.293.867.988.976.0Positive predictive value92.385.785.191.484.689.2Accuracy87.382.587.381.086.083.9See Methods for calculations*PAAT* pulmonary artery acceleration time; *PAD* pulmonary artery deceleration; *PAP* pulmonary artery pressure; *RV* right ventricle

Discussion {#Sec7}
==========

We have demonstrated that pulmonary artery flow is readily detectable using echocardiography and can be used as a screening tool for the evaluation of PAH in a rat model. Furthermore, we have shown that parameters such as echo-TPVR, PAAT, and PAD are associated with the severity of PAH. Since rat models are increasingly used in studies evaluating various therapeutic interventions for PAH, these non-invasive parameters allow identification and quantification of disease progression at multiple time-points, replacing or at least complementing invasive data. Furthermore, we have developed algorithms for the evaluation of PAH that may also have value in the evaluation of PAH in patients.

Invasive PAPs in our study were similar to the values reported in earlier studies of rats with MCT-induced PAH \[[@CR20], [@CR29], [@CR30]\]. Distinction to the high yield of non-invasive echocardiography methods, we measured invasive PAP successfully in only 34 out of 47 cases (72%) with advanced PAH. This experience is in-line with the success rates reported by other investigators: 80% at day 21 and 50% at day 35 (personal communication, Dr Hirofumi Sawada, Stanford University, CA). The difficulty of performing invasive measurements in animals with advanced PAH is an important limitation of all invasive parameters and underscores the importance of innovative non-invasive measurements.

To our knowledge, TPVR has not been studied in rodents using echocardiography. In our study, echo-TPVR values predicted invasive TPVR values but were limited to animals with more advanced PAH with TR jet. Echo-TPVRs were studied only to check whether their use would offer relevant and easily detectable information in this animal model. Both Echo-TPVR formulas 1 and 4, which are simpler measurements, were found to be useful when compared to the diagnostic yield of echo-TPVR formula-2, which is a more complex calculation.

We found tissue Doppler parameter difficult to measure. This failure may be explained by the fact that rats have a much thinner right ventricular wall and a higher heart rate than humans. Additionally, we noticed that Doppler gain settings have a significant influence on IVRT' values. Only 2--4 ms difference in IVRT' corresponds to 10--20% change in this parameter. IVRT' values corrected to RR-interval were similar to the levels observed by Boissiere et al. \[[@CR26]\] (data not shown). Recently, it has been reported that IVRT' \<40 ms has 100% negative predictive value for PAH in humans \[[@CR14]\]. Furthermore, IVRT' is generally a measure of right ventricular diastolic function describing ventricular burden of PAH. Therefore, it has substantial limitations for use in the measurement of PAH. Other ultrasound systems with different filtering algorithms for tissue Doppler signals may have led to better diagnostic yield of tissue Doppler technique but this remains to be studied.

Pulmonary artery acceleration time values in our study were similar to the values observed in earlier studies of rats with MCT-induced PAH \[[@CR30], [@CR31]\]. Jones et al. \[[@CR30]\] reported the correlation of 0.84 between PAAT and invasive PAP only in animals with PAAT between 20 and 32 ms. In our study a comparable correlation was found even without excluding values outside this range. Short PAAT values are likely due to reduced capacitance and the increased impedance of the pulmonary vascular bed causing the deceleration to begin at early systole \[[@CR32]\]. Furthermore, increased stiffness of pulmonary artery may cause short PAAT and rapid PAD by increasing the pulse wave velocity and therefore causing earlier reflection from the periphery resulting in early deceleration \[[@CR33]\].

Previously, Jones et al. \[[@CR30]\] showed that quantification of TR velocity is usually unsuccessful in rats with systolic PAP below 65 mmHg. Our data supports this observation, as we were able to quantify TR velocity from only one rat with invasive systolic PAP below 65 mmHg. Jones et al. \[[@CR30]\] also demonstrated a good correlation (*r* = 0.92) between rat PAP using this method compared to invasive measurement, but the technique succeeded only in six of 61 animals. In our study, the lack of significant correlation between TR velocity derived PAP compared to invasive PAP may be explained by the relatively small range of successful PAP measurements by this particular echo technique. No other studies have evaluated intra- or interobserver variabilities of the invasive PAP or TPVR measurement in the rat model of PAH. Jones et al. \[[@CR30]\] reported the intraobserver and interobserver variability between 3.0 and 3.5% for PAAT by a non-standard method of using twice SD. In our report, all the echocardiographic parameters were found to have low intraobserver and interobserver variability. The exception was IVRT', which had a high interobserver variability and also the quite poor correlation with invasive PAP.

The algorithm of PAAT \<28 ms and PAD \>11.8 m/s^2^ has the best specificity of 97.6% and the algorithm of PAAT \<28 ms or PAD \>11.8 m/s^2^ has the best sensitivity of 82.6% of the studied parameters to detect significant PAH (of note, PAAT alone also has the same sensitivity). Parameter with a high sensitivity is advantageous for detecting established disease before treatment and parameter with a high specificity for excluding animals before further experiments due to failure in the induction of the disease. This is a critical issue in translational studies, as they are usually performed using relatively small treatment groups and are therefore, especially vulnerable for misleading results. The presented algorithms can be employed to ensure disease induction and improve the verity of the data collected.

There are a number of limitations to our study. First, echo-TPVR-formula-2 and invasive-TPVR were both calculated by cardiac outputs derived from non-invasive method. In this regard, it should be highlighted that the purpose of this study was to evaluate whether simple echocardiographic measurements such as those used for the calculation of echo-TPVR-1, 3 and 4 would have value when evaluating rat PAH. Based on our previous published work \[[@CR25]\] non-invasive cardiac output was comparable to the invasive measurement. Additionally, it is well recognized that the presence of moderate to severe TR, as observed in advanced PAH, may lead to inaccurate invasive thermodilution derived cardiac outputs whereas TR has no effect on the echocardiographically derived measurements and this may be preferable as an easier, more reproducible and non-invasive measure of cardiac output. Bland--Altman plots from two recent studies indicate that there may be more differences between thermodilution and Fick methods derived cardiac outputs compared to echocardiography and Fick \[[@CR34], [@CR35]\]. Despite this, we do recognize this point as a limitation of our manuscript but do not believe that the invasive measurements would have altered the results of our findings and in fact, since it is very challenging to make these measurements in rats with significant PAH, we propose that future studies use the non-invasive method proposed here to avoid high animal mortality and allow completion of the research studies in a timely and cost-effective manner. Second, agitated saline or contrast agent was not used to enhance the Doppler signal determining TR velocity, which might have improved yield of successful measurements. However, contrast agents in rats require tail vein cannulation and a separate infusion pump with agitation capability, and importantly it would have potentially influenced the non-invasive nature of our measurements. Third, a correction for heart rate in PAAT measurement was not used. Finally, echocardiographically determined TPVR (formula 1) was not adjusted for right ventricular outflow tract diameter. However, in another study, this correction did not lead to a significant change in the correlation between the methods (*r* = 0.73 vs. *r* = 0.71) \[[@CR13]\].

In addition, it should be noted that the Bland--Altman technique is considered ideal when evaluating agreement between two methods especially when one is comparing measurements, which are expected to give the same values in the ideal situation when the methods do not differ. In our study, only two variables were suitable for assessment with the Bland--Altman method, and this has been reported.

Finally, it should be emphasized that observed values of echocardiographic parameters in this study can be assumed valid only in rats. It has been shown that PAAT values are much higher in humans compared to rats due to lower heart rate \[[@CR36]\]. PAP was measured only in animals with chronic pulmonary hypertension, and our results may not apply to acute PAH.

Conclusion {#Sec8}
==========

In conclusion, we have shown that non-invasive echocardiography allows the measurement of several highly reproducible parameters for evaluation of PAH in a small animal model of which pulmonary artery acceleration time and deceleration are the most practical.
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